Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q2

4583.TEDINET S100OXYH
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥278m2022-01-01 → 2022-06-30StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥385m2021-01-01 → 2021-06-30StandaloneNet sales
Operating income−¥779m2022-01-01 → 2022-06-30StandaloneOperating income
Operating income−¥415m2021-01-01 → 2021-06-30StandaloneOperating income
Ordinary income−¥769m2022-01-01 → 2022-06-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥409m2021-01-01 → 2021-06-30StandaloneOrdinary income
Profit before tax−¥769m2022-01-01 → 2022-06-30StandaloneIncome before income taxes
Profit before tax−¥397m2021-01-01 → 2021-06-30StandaloneIncome before income taxes
Net income−¥771m2022-01-01 → 2022-06-30StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥409m2021-01-01 → 2021-06-30StandaloneProfit loss
Total assets¥1.9bnat 2022-06-30StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.3bnat 2021-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥444mat 2022-06-30StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2022-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2021-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2022-06-30StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2022-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.3bnat 2021-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥660m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥561m2021-01-01 → 2021-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥35m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥341m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥176m2021-01-01 → 2021-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-18.172022-01-01 → 2022-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.532022-04-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.162021-01-01 → 2021-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.162021-04-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio75.3%at 2022-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio85.3%at 2021-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued43,057,600at 2022-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,291,500at 2021-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥239m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-06-30−¥691m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-06-30¥151m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥540m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-06-30−¥215m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-06-30¥103m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-06-30¥103m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-06-30−¥356m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-06-30¥282m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-06-30¥282m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-06-30¥156m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-06-30¥385m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-06-30¥385m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-06-30−¥201m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 436
ItemContextValueUnit
Advances receivedCurrentQuarterInstant_NonConsolidatedMember9600000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember6453000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember5064000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember4821000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember6328000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember392540000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember390017000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember53849000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54059000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember53849000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54059000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember446390000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember444076000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember1515929000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember1695249000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3115710000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember3295030000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-2773693000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-3544466000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1857654000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1445521000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember35394000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember30613000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1893049000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1476135000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2339439000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1920212000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember384932000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember278211000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember126089000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember127082000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember258843000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember151129000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember459373000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember690981000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember214815000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember239364000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember674188000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember930345000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-415345000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-779216000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember15000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember11000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember6770000JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember－JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember－JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember16000000JPY
Other noiPrior1YTDDuration_NonConsolidatedMember378000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-06-30pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-06-30pass